The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: Recommendations by an International TILS Working Group 2014

Annals of Oncology

Volumn 26, Issue 2, 2015, Pages 259-271

  Salgado, R ^a,b   Denkert, C ^c   Demaria, S ^d   Sirtaine, N ^a   Klauschen, F ^c   Pruneri, G ^e   Wienert, S ^c   Van den Eynden, G ^f   Baehner, F L ^g,h   Penault Llorca, F ⁱ   Perez, E A ^j   Thompson, E A ^j   Symmans, W F ^k   Richardson, A L ^l,m   Brock, J ^m,n   Criscitiello, C ^o   Bailey, H ^g   Ignatiadis, M ^a   Floris, G ^p   Sparano, J ^q   Kos, Z ^r   Nielsen, T ^s   Rimm, D L ^t   Allison, K H ^u   Reis Filho, J S ^v   Loibl, S ^w   Sotiriou, C ^a   Viale, G ^e   Badve, S ^x   Adams, S ^d   Willard Gallo, K ^a   Loi, Sherene ^y   more..

^a JULES BORDET INSTITUTE   (Belgium)

^b Department of Anesthesiology and Pain Management   (Belgium)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF ANTWERP   (Belgium)

^g Genomic Health Inc   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITÉ CLERMONT AUVERGNE   (France)

^j MAYO CLINIC   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

^m DANA FARBER CANCER INSTITUTE   (United States)

ⁿ HARVARD MEDICAL SCHOOL   (United States)

^o EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^p UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^q ALBERT EINSTEIN MEDICAL CENTER   (United States)

^r UNIVERSITY HEALTH NETWORK   (Canada)

^s UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^t YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^u STANFORD UNIVERSITY   (United States)

^v MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^w GERMAN BREAST GROUP   (Germany)

^x INDIANA UNIVERSITY   (United States)

^y UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

Breast cancer (BC); Clinical validity; Prediction; Prognosis; Tumor infiltrating lymphocytes (TILs)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

B LYMPHOCYTE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CELL HETEROGENEITY; CORE BIOPSY NEEDLE; DIAGNOSTIC VALUE; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LEUKOCYTE STRUCTURE; LYMPHOCYTE TRANSFORMATION TEST; LYMPHOCYTIC INFILTRATION; MACHINE LEARNING; NONHUMAN; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REPRODUCIBILITY; REVIEW; STROMA CELL; T LYMPHOCYTE; TISSUE SECTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; VALIDITY; BREAST TUMOR; FEMALE; IMMUNOLOGY;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING;

EID: 84924076132     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu450     Document Type: Review

References (51)

1. Demaria S, Pikarsky E, Karin M et al. Cancer and inflammation: promise for biologic therapy. J Immunother 2010; 33: 335-351.
2. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014; 27: 16-25.
3. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
4. Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014 April 8 [epub ahead of print], doi:10.1158/1078-0432.CCR-13-3271.
5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4): 252-264.
6. Willard-Gallo K, Gu-Trantien C, Garaud S et al. Organized immune response in cancer. In: European Patent #12195271, 2012.
7. Galon J, Angell HK, Bedognetti D et al. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39: 11-26.
8. Coussens LM, Pollard JW. Leukocytes in mammary development and cancer. Cold Spring Harb Perspect Biol 2011; 3: pii: a003285, doi: 10.1101/cshperspect. a003285.
9. DeNardo DG, Barreto JB, Andreu P et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
10. Mahmoud SM, Paish EC, Powe DG et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29: 1949-1955.
11. Liu S, Foulkes WD, Leung S et al. Prognostic significance of FOXP3+ tumor infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res 2014; 16: 432.
12. Seo AN, Lee HJ, Kim EJ et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 2013; 109: 2705-2713.
13. Bates GJ, Fox SB, Han C et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24: 5373-5380.
14. Gobert M, Treilleux I, Bendriss-Vermare N et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009; 69: 2000-2009.
15. West NR, Kost SE, Martin SD et al. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer 2013; 108: 155-162.
16. Gu-Trantien C, Loi S, Garaud S et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123: 2873-2892.
17. Teschendorff AE, Gomez S, Arenas A et al. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer 2010; 10: 604.
18. Qi W, Huang X, Wang J. Correlation between Th17 cells and tumor microenvironment. Cell Immunol 2013; 285: 18-22.
19. An T, Sood U, Pietruk T et al. In situ quantitation of inflammatory mononuclear cells in ductal infiltrating breast carcinoma. Relation to prognostic parameters. Am J Pathol 1987; 128: 52-60.
20. Mahmoud SM, Lee AH, Paish EC et al. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 2012; 132: 545-553.
21. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
22. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicinbased chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-867.
23. Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014; 25(8): 1544-1550.
24. Adams S, Demaria S, Goldstein L et al. Prognostic value of tumor-infiltrating lymphocytes (TILs) in Triple Negative Breast Cancers (TNBC) from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014 Jul 28 [epub ahead of print], doi: JCO.2013.55.0491.
25. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14: 1014-1022.
26. Almendro V, Kim HJ, Cheng YK et al. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 2014; 74: 1338-1348.
27. Demaria S, Volm MD, Shapiro RL et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001; 7: 3025-3030.
28. Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 2012; 84: 879-880.
29. Ma Y, Kepp O, Ghiringhelli F et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol 2010; 22: 113-124.
30. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-1452.
31. Ali HR, Provenzano E, Dawson SJ et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12439 patients. Annals of Oncology 2014; 25: 1536-1543.
32. Liu S, Lachapelle J, Leung S et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 2012; 14(2): p.R48.
33. Schalper KA, Velcheti V, Carvajal D et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 2014; 20: 2773-2782.
34. West NR, Milne K, Truong PT et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011; 13(6): R126.
35. Hornychova H, Melichar B, Tomsova M et al. Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest. 2008; 26(10): 1024-1031.
36. Ono M, Tsuda H, Shimizu C et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat 2012; 132(3): 793-805.
37. Yamaguchi R, Tanaka M, Yano A et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol 2012; 43(10): 1688-1694.
38. Oda N, Shimazu K, Naoi Y et al. Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat 2012; 136(1): 107-116.
39. Schmidt M, Hellwig B, Hammad S et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 2012; 18(9): 2695-2703.
40. Issa-Nummer Y, Darb-Esfahani S, Loibl S et al. Prospective validation of immunological infiltrate for prediction of response to neodjuvant chemotherapy in HER2-negative breast cancer-s substudy of the neoadjuvant GeparQuinto trial. PLoS One 2013; 8(12): e79775.
41. Lee HJ, Seo JY, Ahn JH et al. Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer 2013; 16 (1): 32-39.
42. Nabholtz JM, Abrial C, Mouret-Reynier MA et al. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. Ann Oncol 2014; 25: 1570-1577.
43. Ignatiadis M, Singhal SK, Desmedt C et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012; 30(16): 1996-2004.
44. Perez EA, Aubrey E, Keith Andersen SK et al. Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. J Clin Oncol 2014; 32 (suppl 5s): abstr 509.
45. Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Res 2013; 73(24 Suppl): abstract S1-05.
46. Denkert C, Loibl S, Salat C et al. Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). J Clin Oncol 2013; abstr S1-06; in press.
47. Dieci MV, Criscitiello C, Goubar A et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 2014; 25: 611-618.
48. Bendall SC, Simonds EF, Qiu P et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011; 332(6030): 687-696.
49. Vinayak S, Gray RJ, Adams S et al. Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105. J Clin Oncol 2014; 32: 5s. (suppl; abstr 1000).
50. Schalper KA, Brown J, Carvajal-Hausdorf D et al. Objective measurement and clinical significance of TILs in non-small cell lung cell cancer (NSCLC), in press.
51. Brown J, Wimberly H, Lannin D et al. Multiplexed quantitative analysis of CD3, CD8 and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2014 September 25 [epub ahead of print], doi: 10.1158/1078-0432.CCR-14-1622.